Munich, Germany, June 23, 2022 - neurocare group AG (“neurocare” or the “Company”), a leading innovator in personalized mental health and performance empowering clinicians to deliver best practice,
Transcranial alternating current stimulation (tACS) is a non-invasive brain-stimulating technique. tACS uses electrical currents to change brain activity and ultimately alter behaviour. This
This week is Men's Health Week and at neurocare we want to take this chance to reflect upon five core factors of men's health that become more relevant in the backdrop of the surging economic and
Our training courses are designed to instruct clinicians, academics and researchers in the use of neuromodulation technology, with a goal to apply these techniques in clinical practices or research settings. Under the guidance of our expert trainers, students receive substantial hands-on experience with rTMS, tDCS and neurofeedback technology and its application. Over the last 10 years we have trained more than 1,000 professionals from over 30 countries in the use of neuromodulation techniques. We have continually received outstanding feedback from our trainees, with an average evaluation of 8.9/10.
For more than ten years the neuroConn brand has been associated with practice-oriented medical technology used in neuroscience and clinical research, as well as in the diagnosis and treatment of neuropsychological disorders. In close cooperation with leading research institutions and clinics worldwide, neuroConn technology is designed following the latest medical research standards. In this way we provide users with standardised and clinically evaluated protocols in transcranial Electrical Stimulation (tDCS, tACS, tRNS) as well as Neurofeedback of Slow Cortical Potentials.
